Regency Capital Management Inc. DE Has $5.01 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

Regency Capital Management Inc. DE lessened its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 8.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 609,424 shares of the company’s stock after selling 57,887 shares during the period. Aura Biosciences comprises 2.7% of Regency Capital Management Inc. DE’s holdings, making the stock its 15th largest holding. Regency Capital Management Inc. DE owned 1.22% of Aura Biosciences worth $5,009,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after buying an additional 8,194 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after acquiring an additional 15,000 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences during the second quarter worth $119,000. Finally, SG Americas Securities LLC acquired a new stake in Aura Biosciences during the 3rd quarter worth about $169,000. 96.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research boosted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Finally, Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $7.89 on Friday. The firm has a fifty day moving average price of $8.38 and a two-hundred day moving average price of $8.92. The company has a market cap of $394.11 million, a price-to-earnings ratio of -4.56 and a beta of 0.30. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Equities research analysts expect that Aura Biosciences, Inc. will post -1.67 EPS for the current fiscal year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Los Pinos Elisabet De sold 9,200 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the transaction, the insider now directly owns 320,647 shares of the company’s stock, valued at approximately $3,443,748.78. This trade represents a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,531 shares of company stock worth $345,454 in the last ninety days. 5.40% of the stock is owned by company insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.